高眼圧症治療市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、投与経路別、流通チャネル別、地域別、競合別、2020～2030年

高眼圧症治療の世界市場規模は2024年に36億7,000万米ドルとなり、2030年までの年間平均成長率（CAGR）は3.82％と、予測期間中に力強い成長が予測されています。

近年、高眼圧症の有病率が上昇し、高度な治療ソリューションに対する需要が高まっていることを背景に、同市場は大きな発展を遂げています。高眼圧症は眼内圧の上昇を特徴とし、放置すると緑内障に至る可能性があり、世界的に不可逆的な失明の主要原因のひとつとなっています。その結果、高眼圧症治療市場は眼科医療分野の重要なセグメントです。例えば、2024年1月、インディアナ大学医学部の研究者は、緑内障の画期的な治療法を開発する革新的なイニシアチブを開始しました。この研究は、米国国立眼病研究所から200万米ドルのR01助成金を受けています。

主な市場促進要因

高齢化

主な市場課題

過小診断と認識不足

主な市場動向：

低侵襲手術技術

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の高眼圧症治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（高眼圧症、緑内障）
  • 投与経路別（経口、非経口、その他）
  • 流通チャネル別（小売薬局、オンライン薬局、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ
  • タイプ別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の高眼圧症治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の高眼圧症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の高眼圧症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の高眼圧症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの高眼圧症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の高眼圧症治療市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Angelini Spa
• Laboratorios Sophia
• Neurim Pharmaceuticals Ltd
• Nicox SA
• Novartis AG.
• Aerie Pharmaceuticals, Inc.
• Abbvie, Inc
• Angelini Pharma S.p.a.
• Chong Kun Dang pharmaceutical Corp
• Lee Pharma Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

The global Ocular Hypertension Treatment Market was valued at USD 3.67 billion in 2024 and is projected to experience robust growth during the forecast period, with a compound annual growth rate (CAGR) of 3.82% through 2030. The market has seen significant development in recent years, driven by the rising prevalence of ocular hypertension and the increasing demand for advanced therapeutic solutions. Ocular hypertension is characterized by elevated intraocular pressure, which, if left untreated, can lead to glaucoma-one of the leading causes of irreversible blindness worldwide. As a result, the ocular hypertension treatment market is a critical segment of the ophthalmic healthcare sector. For example, in January 2024, researchers at Indiana University School of Medicine launched an innovative initiative to develop groundbreaking therapy for glaucoma, supported by a USD 2 million R01 grant from the National Eye Institute.

Key Market Drivers:

Aging Population

The growing aging population is a key driver of the expanding global ocular hypertension treatment market. As individuals age, they become more susceptible to ocular hypertension due to age-related changes in the eye's drainage system, which can hinder the flow of aqueous humor and increase intraocular pressure. The World Health Organization forecasts that the global population aged 60 and older will more than double by 2050, reaching nearly 2.1 billion people. This demographic shift will result in a rise in the prevalence of ocular hypertension and glaucoma among the elderly, creating a larger patient base in need of treatment. As the population ages, there will be an increased demand for both pharmaceutical and surgical interventions, including minimally invasive procedures like Micro-Invasive Glaucoma Surgery (MIGS). These treatments offer less invasive and more efficient solutions for managing intraocular pressure. Consequently, the global ocular hypertension treatment market is positioned for steady growth, catering to the rising healthcare needs of older individuals and contributing to better vision preservation and reduced blindness rates.

Key Market Challenges:

Underdiagnosis and Lack of Awareness

Ocular hypertension is often a silent condition, with no obvious symptoms, making it challenging to detect early. Many individuals are unaware of the condition and its potential progression to glaucoma, which leads to a delay in diagnosis and intervention. This lack of awareness poses a significant barrier to market growth, as untreated ocular hypertension can advance to glaucoma, resulting in irreversible vision loss. Public ignorance about the importance of regular eye check-ups further complicates early detection efforts. Raising awareness about ocular hypertension and its connection to glaucoma is essential for capturing potential patients early, when treatments are most effective. Healthcare professionals, ophthalmologists, and public health campaigns must play a key role in educating individuals about the risks of ocular hypertension and the need for proactive eye care.

Key Market Trends:

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques are transforming the treatment landscape for ocular hypertension. Traditionally, managing elevated intraocular pressure involved more invasive surgeries, often with longer recovery times and higher risks. However, the development of Micro-Invasive Glaucoma Surgery (MIGS) has introduced a less invasive approach that reduces surgical trauma while targeting the underlying causes of elevated intraocular pressure. MIGS has numerous benefits for both patients and healthcare providers, including shorter recovery periods, lower complication rates, and improved patient outcomes. The growing adoption of MIGS is expected to continue driving the ocular hypertension treatment market, providing a shift toward more efficient and patient-friendly treatment options.

Key Market Players:

• Angelini Spa
• Laboratorios Sophia
• Neurim Pharmaceuticals Ltd
• Nicox SA
• Novartis AG
• Aerie Pharmaceuticals, Inc.
• AbbVie, Inc.
• Angelini Pharma S.p.a.
• Chong Kun Dang Pharmaceutical Corp
• Lee Pharma Ltd

Report Scope:

This report segments the global ocular hypertension treatment market into various categories and provides a detailed analysis of trends:

By Type:

• Intraocular Hypertension
• Glaucoma

By Route of Administration:

• Oral
• Parenteral
• Other

By Distribution Channel:

• Retail Pharmacy
• Online Pharmacy
• Other

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section provides a comprehensive analysis and profiling of major companies operating in the global ocular hypertension treatment market.

Available Customizations:

TechSci Research offers tailored customization options for this market report, allowing adjustments to meet specific company needs. Customization options include detailed analysis and profiling of up to five additional market players.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Ocular Hypertension Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Intraocular Hypertension, Glaucoma)
  • 4.2.2. By Route Of Administration (Oral, Parenteral, Other)
  • 4.2.3. By Distribution Channel (Retail Pharmacy, Online Pharmacy, Other)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Route Of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Ocular Hypertension Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Route Of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Ocular Hypertension Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Route Of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Ocular Hypertension Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Route Of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Ocular Hypertension Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Route Of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Ocular Hypertension Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Route Of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Ocular Hypertension Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Route Of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Ocular Hypertension Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route Of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Ocular Hypertension Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route Of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Ocular Hypertension Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route Of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Ocular Hypertension Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route Of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Ocular Hypertension Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Route Of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Ocular Hypertension Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Route Of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Ocular Hypertension Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route Of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Ocular Hypertension Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route Of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Ocular Hypertension Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route Of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Ocular Hypertension Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route Of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Ocular Hypertension Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route Of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Ocular Hypertension Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route Of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Ocular Hypertension Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route Of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Ocular Hypertension Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route Of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Ocular Hypertension Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route Of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Ocular Hypertension Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route Of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Ocular Hypertension Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route Of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Ocular Hypertension Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route Of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Ocular Hypertension Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Angelini Spa
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Laboratorios Sophia
• 14.3. Neurim Pharmaceuticals Ltd
• 14.4. Nicox SA
• 14.5. Novartis AG.
• 14.6. Aerie Pharmaceuticals, Inc.
• 14.7. Abbvie, Inc
• 14.8. Angelini Pharma S.p.a.
• 14.9. Chong Kun Dang pharmaceutical Corp
• 14.10. Lee Pharma Ltd

15. Strategic Recommendations

16. About Us & Disclaimer